Pfizer tests new drug in people with kidney problems

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female of nonchildbearing potential, between the ages of 18 and 80 years, at the screening visit. * BMI of 17.5 to 40.0 kg/m2 (inclusive), and a total body weight ≥45 kg (99 lbs). * Stable renal function, defined as ≤25% difference between 2 measurements of eGFR. * Group 1 only: at screening, no clinically relevant abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, ECG and clinical laboratory tests. * Group 1 only: normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from the screening visits. * Groups 2 \& 3 only: good general health considered acceptable with the expected health status of individuals with chronic renal impairment. * Groups 2 \& 3 only: chronic renal impairment, defined by the following mean eGFR criteria (based on screening visits): * Severe RI: 15 ≤ mean eGFR \<30 mL/min, not requiring hemodialysis. * Moderate RI: 30 ≤ mean eGFR \<60 mL/min. Exclusion Criteria: * Any condition possibly affecting drug absorption. * At screening, a positive result for HIV antibodies. * History of renal, liver, or heart transplantation. * Urinary incontinence without catheterization. * Evidence of a prothrombotic state, including history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis, or known genetic predisposition. * Use of an investigational product within 30 days or 5 half-lives (whichever longer). * A positive urine drug test or breath alcohol test at screening or admission to study clinic. * Group 1 only: evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease. * Group 1 only: screening ECG demonstrating QTcF interval \>450 ms or a QRS interval \>120 ms. * Group 1 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg * Group 2 \& 3 only: presence of acute renal disease * Group 2 \& 3 only: requiring dialysis or anticipated need for dialysis * Group 2 \& 3 only: listed for solid organ transplantation * Groups 2 \& 3 only: persistent severe, uncontrolled hypertension at screening, admission to study clinic, or pre-dose on Day 1. * Groups 2 \& 3 only: screening ECG demonstrating a QTcF interval \>470 ms or a QRS interval \>120 ms. * Groups 2 \& 3 only: unstable medical conditions or comorbidities that would interfere with study participation